We had several financings that didnt make the 12/1 edition of Vital Signs.

Biolexis Therapeutics – a company using AI for metabolic drug discovery, raised a $10M Series A. (American Fork, UT)

Aperiam Bio – a protein engineering company, raised a $9M Seed extension.(Brooklyn, NY)

Arrivo Bioventures – a drug developer, raised a $45M Series B.(Morrisville, NC)